AGM Statement

12 June 2014

Source BioScience plc

('Source BioScience', the 'Group')

ANNUAL GENERAL MEETING STATEMENT

Laurie Turnbull, Chairman of Source BioScience, will be making the following comments at the 2014 Annual General Meeting to be held today at 10.30am:

"Since our last Annual General Meeting, twelve months ago, the Group has undergone a period of major transformation and the acquisitions made during 2013 have created significant opportunities, particularly for the second half of 2014. The Group continues to trade in line with management's expectations for the full year.

Healthcare and Diagnostics

The Diagnostics activities of this division continue to perform strongly with a major component of the growth resulting from the Sexually Transmitted Infection ('STI') testing service launched during 2013. A number of STI screening and integrated sexual health tenders have been secured, with further contracts due to come on stream as the year progresses.

The Healthcare and Diagnostics product portfolio, which includes cytology e.g. cervical cancer screening and serology e.g. blood testing products, has seen revenue increase compared with last year, driven by growth of the serology business. Support for the NHS Cervical Screening Programme continues to plan and an existing liquid based cytology supply agreement has been renewed with a current NHS customer.

LifeSciences

Source BioScience maintains a leading position in the UK as a provider of DNA sequencing and has recently renewed its position as a preferred provider to the Research Councils UK. Sequencing revenue growth is being driven by the expansion of the laboratory network, with additional European and US sequencing facilities enhancing our global presence and enabling access to new geographic markets.

The roll out of the Group's product portfolio under the reSourceTM brand and expansion of the product portfolio, supported by the GenomeCube® search engine and e-commerce platform, is being progressed. Key initiatives are planned for roll-out during the second half of the year and the Directors believe that the reSourceTM brand will ultimately enable globalisation of the products business.

Stability and Bio Storage

The performance of the Stability and Bio Storage division remains in line with expectations and new opportunities with biopharma customers have already been crystallised. These opportunities result from the combination of the Group's stability storage capability and laboratory services expertise, providing biopharma customers with a single site solution for storage and downstream analysis requirements. This offering is attracting new customers and the pipeline of projects is expanding.

The established stability storage facilities in Atlanta and Los Angeles have provided the foundation from which to roll out the Group's DNA sequencing service and product portfolio in the USA as well as providing local biopharma customers with the enhanced storage and analysis service.

Outlook

Results for the year ended 31 December 2013 demonstrated another year of strong growth for the business and trading for the early part of 2014 continues to build on the robust operational performance of the Group.

We look forward to updating shareholders further following the publication of our Half Year Report for the six months ending 30 June 2014, anticipated to be released in August 2014."

--- ENDS ---

For further information, please contact:

Source BioScience plc

Dr Nick Ash, CEO

Tel: +44 (0) 115 973 9010

Email: [email protected]

www.sourcebioscience.com

For investor and media enquiries:

N+1 Singer (Financial Advisor, Sponsor and Broker)

Aubrey Powell

Tel: +44 (0)203 201 3710

www.nplus1singer.com

Instinctif Partners (PR Agency)

Melanie Toyne-Sewell/Jen Lewis

Tel: +44 (0)207 457 2020

Email: [email protected]

About Source BioScience

Source BioScience is a trusted provider of state-of-the-art products and services to the healthcare and clinical, life and applied scientific and biopharma industries. It is an international business with centres in four countries and customers in over 90 countries. The Group offers a complementary portfolio of products and services that share common technologies, lab processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These products and services are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange (LSE: SBS).